

Article Review

The Gut Microbiome and Human Health: Insights from Recent Research

Semir Bechir Suheil GAOUAR*

Applied genetics in agriculture, ecology and public health laboratory, University of Tlemcen.

*Corresponding author: Gaouar S B S; University of Tlemcen. E-mail: suheilgaouar@gmail.com

Article history: Received: January 5, 2025, revised: January 5, 2025, Accepted: January 6, 2025

المخلص

الميكروبيوم المعوي، وهو مجتمع معقد من الكائنات الدقيقة التي تعيش في الجهاز الهضمي البشري، يلعب دورًا حيويًا في الحفاظ على الصحة العامة. تستعرض هذه المراجعة التطورات الحديثة في دراسة الميكروبيوم المعوي، مع تسليط الضوء على التقنيات الحديثة مثل الميتاجينوميكس، الميتاترانسكريبتيكس، الميتابولوميكس، تسلسل الخلايا المفردة، والمعلوماتية الحيوية. كما نناقش تطور الميكروبيوم المعوي البشري من خلال استعراض وجهات النظر التاريخية وتأثير التغيرات في نمط الحياة، بالإضافة إلى الفروقات بين ميكروبيومات البشر القدامى والمعاصرين. تتعمق هذه المراجعة في التأثيرات الفسيولوجية للميكروبيوم المعوي على الصحة الهضمية، والتمثيل الغذائي، وصحة القلب والأوعية الدموية، مع التركيز على دوره الحيوي في هذه المجالات. ويتم تسليط الضوء بشكل خاص على العلاقة بين الميكروبيوم المعوي والسمنة، بما في ذلك الآليات، والنتائج البحثية، والتدخلات المحتملة. علاوة على ذلك، نستكشف التأثيرات النفسية من خلال محور الأمعاء والدماغ ودوره في الصحة النفسية. كما يتم تناول التأثيرات المناعية، مع التركيز على دور الميكروبيوم في تعديل الجهاز المناعي وعلاقته بأمراض المناعة الذاتية. يتم أيضًا تحليل التأثيرات الجينية واللاجينية للميكروبيوم على الجينات البشرية والتعبير الجيني، إلى جانب الفروقات العرقية في تكوين الميكروبيوم الناتجة عن العوامل الجينية والبيئية. تتناقص المراجعة التأثيرات البيئية مثل النظام الغذائي، والجغرافيا، ونمط الحياة، والملوثات، وتأثير الأدوية والمضادات الحيوية على ميكروبيوم الأمعاء. وتختتم المراجعة باستكشاف الإمكانيات العلاجية، بما في ذلك البروبيوتيك، والبريبايوتيك، وزرع ميكروبيوم البراز (FMT)، والطب الشخصي المبني على ملفات تعريف الميكروبيوم. تهدف هذه المراجعة الشاملة إلى تلخيص النتائج الرئيسية، وإبراز الآثار المترتبة على الأبحاث المستقبلية والممارسات السريرية، والتأكيد على أهمية الميكروبيوم المعوي في صحة الإنسان.

الكلمات المفتاحية: الميكروبيوم المعوي، صحة الإنسان، تقنيات البحث، التأثيرات الفسيولوجية، التأثيرات النفسية، التأثيرات المناعية، التأثير الجيني واللاجيني، الفروقات العرقية، العوامل البيئية، التغذية، الأدوية، تطور الميكروبيوم، السمنة.

Abstract

The gut microbiome, a complex community of microorganisms residing in the human gastrointestinal tract, plays a crucial role in maintaining overall health. This review explores recent advancements in the investigation of the gut microbiome, highlighting cutting-edge techniques such as metagenomics, metatranscriptomics, metabolomics, single-cell sequencing, and bioinformatics. We discuss the evolution of the human gut microbiome, examining historical perspectives and the influence of lifestyle changes, as well as differences between ancient and modern human microbiomes. This review delves into the physiological impacts of the gut microbiome on digestive, metabolic, and cardiovascular health, emphasizing its significant role in these areas. Special attention is given to the connection between the gut microbiome and obesity, detailing mechanisms, research findings, and potential interventions. Furthermore, we explore the psychological impacts through the gut-brain axis and its influence on mental health. Immunological impacts are also covered, focusing on the microbiome's role in immune system modulation and its link to autoimmune diseases. The genetic and epigenetic influences of the microbiome on host genetics and gene expression are analyzed, along with ethnic differences in microbial composition driven by genetic and environmental factors. Environmental influences such as diet, geography, lifestyle, pollutants, and the effects of medication and antibiotics on the gut microbiota are discussed. The review concludes with an exploration of therapeutic potentials, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and personalized medicine based on microbiome profiles. This comprehensive review aims to summarize key findings, highlight the implications for future research and clinical practice, and underscore the significance of the gut microbiome in human health.

Keywords: Gut Microbiome, Human Health, Investigation Techniques, Physiological Impact, Psychological Impact, Immunological Impact, Genetic and Epigenetic Influence, Ethnic Differences, Environmental Factors, Nutrition, Medication, Microbiome Evolution, Obesity.

Introduction to Gut Microbiome and Human Health

The gut microbiome, an intricate ecosystem of microorganisms residing in the human gastrointestinal tract, plays a crucial role in maintaining health. This community, which includes bacteria, archaea,

viruses, and fungi, influences various physiological, psychological, and immunological processes (Gomaa et al., 2020).

High-throughput sequencing technologies, such as next-generation sequencing and metagenomics, have revolutionized our understanding of the gut microbiome, revealing its complexity and its significant role in human health and disease (Wensel et al., 2022). For instance, gut bacteria like Bacteroides and Firmicutes are involved in the breakdown of complex carbohydrates, aiding in digestion and energy production (Payling et al., 2020).

The gut microbiome aids in the digestion of food, the synthesis of essential vitamins (such as vitamin K and certain B vitamins), and the protection against pathogenic microorganisms by maintaining the integrity of the gut barrier and modulating immune responses (Cryan & Dinan, 2017). Additionally, short-chain fatty acids (SCFAs) produced by gut microbes from dietary fibers are critical for colon health and play a role in regulating metabolism and inflammation (Xu et al., 2022).

The gut-brain axis is a bidirectional communication pathway between the gut microbiome and the brain, implicating gut microbes in mental health and neurological functions. Studies have shown that gut microbiota can influence mood, behavior, and cognitive functions through the production of neurotransmitters and modulation of immune signaling (Chen et al., 2021). Furthermore, the gut microbiome is essential for the development and function of the immune system, helping to shape immune responses and maintain immune homeostasis (Belkaid & Harrison, 2017).

Despite its importance, the gut microbiome faces numerous challenges. Dietary changes, such as increased consumption of processed foods and reduced fiber intake, can disrupt microbial balance (Blaser, 2016). Environmental factors, including pollution and lifestyle changes, as well as the widespread use of antibiotics, can lead to dysbiosis—an imbalance in the microbial community that is associated with various diseases, including inflammatory bowel disease, obesity, diabetes, and mental health disorders (Singh et al., 2021).

Understanding the interactions within the gut microbiome and its relationship with the human host is vital for developing targeted therapeutic strategies. Future research is expected to focus on personalized nutrition and medicine, which could tailor dietary and therapeutic interventions based on an individual's unique microbiome composition (Kviatcovsky et al., 2021). Additionally, advancements in probiotics, prebiotics, and microbiome transplantation hold promise for restoring and maintaining a healthy gut microbiome (Shaheen et al., 2022).

This review aims to provide a comprehensive understanding of the gut microbiome's role in human health by exploring recent investigation techniques, physiological impacts, and therapeutic potentials. It will address how the gut microbiome affects digestion, metabolism, immune response, and mental health, and consider the genetic and environmental factors influencing its composition.

The review covers various aspects of gut microbiome research, including metagenomics, metatranscriptomics, metabolomics, single-cell sequencing, and bioinformatics. These techniques have enhanced our understanding of microbial diversity, function, and interactions. The review also examines the evolution of the gut microbiome, its physiological, psychological, and immunological impacts, genetic and epigenetic influences, ethnic differences, and the effects of environmental and nutritional factors. Finally, it discusses the therapeutic potential of microbiome-targeted interventions and future research directions, highlighting the promise of probiotics, prebiotics, and personalized medicine.

Genetic and Epigenetic Influences

The interplay between genetics, epigenetics, and the microbiome is a rapidly evolving field that highlights how microbial communities influence host biology beyond mere genetic sequences. Both host genetics and microbiome interactions shape individual health outcomes, and epigenetic modifications play a critical role in mediating these effects.

Microbiome and Host Genetics

The relationship between the microbiome and host genetics is a dynamic and reciprocal one. Host genetic factors can influence the composition and diversity of the gut microbiota, while the microbiome can, in turn, affect the expression of host genes. This interplay has been described as a form of co-evolution, where both the microbiome and the host adapt to each other's presence (Groussin et al., 2020).

Host genetic variations, such as single nucleotide polymorphisms (SNPs), can impact microbial diversity and community structure. For instance, genetic differences in immune system genes, such as those encoding Toll-like receptors (TLRs) or other pattern recognition receptors, have been shown to affect microbial composition (Yoo et al., 2020). Furthermore, studies have identified specific genetic loci associated with variations in gut microbiome composition, suggesting the role of host genetics in shaping microbial communities (Kurilshikov et al., 2021).

Conversely, the microbiome can influence host gene expression and contribute to phenotypic traits. For example, certain gut bacteria can modulate the expression of genes involved in metabolism, immune response, and inflammation, thereby impacting health outcomes (Gasaly et al., 2021). Recent research using germ-free mouse models and microbiome transplantation studies has demonstrated how specific microbial strains can alter gene expression patterns in the host, providing insights into the functional interactions between microbes and host genetics (Belkaid & Hand, 2014).

Epigenetic Modifications

Microbiota-induced epigenetic modifications are emerging as a crucial mechanism through which gut microbes influence host gene expression and health. Epigenetic changes, such as DNA methylation, histone modifications, and non-coding RNA expression, can be influenced by microbial metabolites and microbial-induced signaling pathways.

Short-chain fatty acids (SCFAs), produced by gut bacteria through fiber fermentation, have been shown to impact epigenetic regulation. SCFAs such as butyrate can inhibit histone deacetylases (HDACs), leading to changes in histone acetylation and gene expression (Van der Hee & Wells 2021). This epigenetic modulation affects genes related to inflammation, metabolism, and cancer, highlighting the role of microbiota in influencing epigenetic landscapes (Dai et al., 2020).

Microbiota-driven epigenetic changes have implications for various diseases. For instance, alterations in DNA methylation patterns induced by microbiota have been linked to inflammatory bowel diseases (IBD), obesity, and cancer (Deris Zayeri et al., 2023). Understanding these interactions provides new avenues for therapeutic interventions, such as targeting microbial metabolites to modulate epigenetic modifications and improve health outcomes.

Advances in high-throughput sequencing technologies and epigenomic profiling have enhanced our ability to study microbiome-mediated epigenetic changes. Multi-omics approaches integrating genomics, transcriptomics, and epigenomics are providing comprehensive insights into how microbiota interact with host genetics and epigenetic mechanisms (Chu et al., 2021).

Investigation Techniques of the Gut Microbiome

Metagenomics

Metagenomics is a powerful technique that enables the study of genetic material recovered directly from environmental samples, bypassing the need to culture individual species. This approach provides comprehensive insights into microbial community composition and functional potential by sequencing DNA extracted from the gut microbiome (Almeida et al., 2019).

Advances in DNA sequencing technologies, particularly next-generation sequencing (NGS) and third-generation sequencing (TGS) have significantly enhanced the resolution and throughput of metagenomic studies. This method has revolutionized microbiome research by allowing the identification of a vast array of microbial taxa, including those that are difficult or impossible to culture in the laboratory (Wensel et al., 2022). Metagenomics can reveal both the taxonomic composition and the functional capabilities of microbial communities, providing insights into their roles in health and disease (Armour et al., 2019).

Once extracted, the DNA is sequenced using platforms like Illumina (for short reads ; Known for its high accuracy and massive parallel sequencing capabilities, Illumina sequencing generates short reads (typically 150-300 base pairs) that are ideal for analyzing microbial community structure (Wensel et al., 2022), PacBio, or Oxford Nanopore (for long reads ; These platforms provide longer reads (up to tens of thousands of base pairs), which are beneficial for resolving complex regions and assembling complete genomes from metagenomic data (Amarasinghe et al., 2020), each offering different strengths in read length, accuracy, and throughput (Almeida et al., 2019). There are two main approaches in metagenomics: shotgun metagenomics and 16S rRNA gene sequencing. Shotgun metagenomics

sequences all the DNA present in a sample, offering a comprehensive view of the microbial diversity and their functional genes. This approach allows for the detection of novel genes and the reconstruction of genomes from complex communities (Shaffer et al., 2022). In contrast, 16S rRNA gene sequencing focuses on amplifying and sequencing a specific region of the ribosomal RNA gene, which is conserved among bacteria but variable enough to distinguish between different taxa. This method is less comprehensive but more cost-effective and widely used for microbial community profiling (Fukuda et al., 2016).

Post-sequencing, bioinformatics tools are employed to assemble the reads into longer sequences, annotate genes, and predict the functional potential of the microbiome. Popular tools include MetaPhlAn (For profiling the composition of microbial communities (Beghini et al., 2021)), QIIME 2 (For a comprehensive analysis of microbiome data, including diversity metrics and taxonomic classification (Bolyen et al., 2019)), MEGAHIT and SPAdes (For metagenome assembly (Fuentes-Trillo et al., 2021)). Functional annotation of metagenomic sequences is performed using databases such as KEGG, COG, and eggNOG, which link sequences to known metabolic pathways and functions (Sequeira et al., 2022). Tools like HUMAnN2 integrate these annotations to provide insights into the metabolic capabilities of microbial communities (Maranga et al., 2023).

Metagenomic studies of the gut microbiome have unveiled a complex and dynamic ecosystem. For instance, research has shown that the gut microbiome consists of core microbial communities that perform essential functions, such as nutrient metabolism, immune modulation, and protection against pathogens (Almeida et al., 2019). Moreover, metagenomics has revealed how factors like diet, antibiotics, and diseases impact the composition and function of the gut microbiome. For example, alterations in the gut microbiome have been linked to conditions such as obesity, diabetes, inflammatory bowel disease, and mental health disorders (Gomaa et al., 2020).

The future of metagenomics lies in integrating multi-omics approaches, such as metatranscriptomics, metaproteomics, and metabolomics, to obtain a holistic view of microbial communities and their interactions with the host. This integrated approach can provide deeper insights into the functional dynamics of the microbiome and its role in health and disease (Arıkan & Muth, 2023).

However, challenges remain in metagenomic data analysis, including the need for improved bioinformatics tools and databases for the accurate interpretation of sequencing data. Additionally, the complexity and diversity of microbial communities necessitate large-scale studies to capture the full extent of microbial variability and its implications (Escalas et al., 2019).

Metatranscriptomics

Metatranscriptomics analyzes RNA transcripts to understand active microbial functions and interactions within the gut ecosystem. By examining the transcriptome—the complete set of RNA molecules produced in the microbiome—researchers can gain a dynamic view of microbial activity, identifying which genes are actively expressed under various conditions (Bashiardes et al., 2016).

Metatranscriptomics involves the extraction and sequencing of RNA from microbiome samples, providing insights into the functional state of microbial communities. This approach allows researchers to distinguish between active and dormant microorganisms, offering a more detailed understanding of microbial roles in health and disease (Ojala et al., 2023). Unlike metagenomics, which reveals potential functional capabilities based on genetic material, metatranscriptomics identifies which genes are actively being transcribed, reflecting real-time microbial responses to environmental changes.

The metatranscriptomic workflow includes several key steps: RNA extraction, RNA sequencing (RNA-Seq), and bioinformatics analysis. RNA-Seq technologies, such as Illumina and PacBio, enable the high-throughput sequencing of RNA transcripts, producing large datasets that require sophisticated computational tools for analysis. RNA-seq can be performed using short-read or long-read sequencing platforms. Illumina sequencing is widely used due to its high accuracy and throughput, generating millions of short reads (75-150 bp). Long-read platforms like PacBio and Oxford Nanopore provide full-length transcript sequences, which are advantageous for resolving complex transcript isoforms and gene structures (Stark et al., 2019). Key bioinformatics approaches include quality control, sequence alignment, and differential expression analysis, which help identify active genes and pathways; Read Alignment and Quantification (Sequencing reads are aligned to a reference genome or transcriptome using tools like STAR and HISAT2. These aligners are optimized for speed and accuracy, ensuring

high-quality mapping of reads (Dobin et al., 2013), Gene and Isoform Quantification (Transcript abundance is quantified using software such as RSEM and Kallisto. These tools estimate the number of reads mapping to each gene or isoform, providing a measure of expression levels (Bray et al., 2016), Differential Expression Analysis (Tools like DESeq2 and edgeR) are used to identify differentially expressed genes between conditions. These tools apply statistical models to determine significant changes in gene expression (Zhang et al., 2014). Functional Analysis (Pathway Analysis: Identifying the biological pathways and processes affected by differentially expressed genes is crucial for understanding the functional implications of transcriptomic changes. Tools like GSEA (Gene Set Enrichment Analysis) and DAVID (Database for Annotation, Visualization, and Integrated Discovery) are commonly used for this purpose (Nguyen et al., 2019). Single-Cell RNA-Seq: Single-cell RNA sequencing (scRNA-seq) provides transcriptomic profiles at the single-cell level, revealing cellular heterogeneity and enabling the study of complex tissues and developmental processes. Technologies like 10x Genomics and Smart-seq are popular for scRNA-seq (Conte et al., 2024).

Metatranscriptomic studies of the gut microbiome have revealed significant insights into microbial activity and its impact on host physiology. For example, research has shown that microbial gene expression in the gut is influenced by diet, circadian rhythms, and host immune responses (Choi et al., 2021). Metatranscriptomics has also been used to investigate how gut microbiota contribute to metabolic functions, such as the production of short-chain fatty acids (SCFAs) from dietary fibers, which play a crucial role in colon health and systemic metabolism (Iablokov et al., 2021).

Additionally, metatranscriptomics has shed light on microbial interactions and community dynamics. For instance, studies have demonstrated how microbial consortia coordinate the degradation of complex polysaccharides and the synthesis of essential vitamins and amino acids (Jiang et al., 2023). These findings highlight the collaborative nature of microbial communities and their importance in maintaining gut homeostasis.

Despite its potential, metatranscriptomics faces several challenges. RNA is less stable than DNA, making sample preservation and RNA extraction more difficult. Moreover, distinguishing between host and microbial RNA can be challenging, requiring rigorous bioinformatics approaches to accurately attribute transcripts (Mukherjee et al., 2023). Additionally, the vast diversity and variability of microbial communities necessitate large-scale studies and robust computational tools for meaningful analysis (Maranga et al., 2023).

Future directions in metatranscriptomics include the integration of multi-omics approaches, combining metatranscriptomics with metagenomics, metaproteomics, and metabolomics to gain a comprehensive understanding of microbial functions and interactions. Advances in single-cell transcriptomics and spatial transcriptomics also hold promise for uncovering the heterogeneity of microbial activity within complex ecosystems (Dar et al., 2021).

Metabolomics

Metabolomics examines the complete set of small-molecule metabolites found within a biological sample, providing insights into the biochemical activities and pathways influenced by gut microbes. This approach helps in linking microbial activity to host physiology and disease states, offering a comprehensive view of metabolic interactions and their impacts on health.

The technical process of metabolomics involves several key steps: sample preparation, metabolite extraction, analysis, and data interpretation. Proper collection and storage of biological samples (e.g., blood, urine, feces) are crucial to prevent degradation or alteration of metabolites. Samples are often stored at -80°C to maintain integrity (Dunn et al., 2011). Different extraction methods are used based on the sample type and the metabolites of interest. Common solvents include methanol, acetonitrile, and water. The choice of solvent and extraction method can significantly impact the metabolite profiles obtained (Roopashree & Naik, 2019).

Mass Spectrometry (MS) is widely used in metabolomics for its high sensitivity and ability to identify and quantify a broad range of metabolites. Techniques include gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS). GC-MS is suitable for volatile compounds, whereas LC-MS is used for a wider range of metabolites (Zeki et al., 2020).

Nuclear Magnetic Resonance (NMR) Spectroscopy provides detailed information on the structure and concentration of metabolites. Although less sensitive than MS, NMR is highly reproducible and non-destructive, making it suitable for quantifying metabolites in complex mixtures (Emwas et al., 2019).

Raw data are preprocessed to remove noise and correct for batch effects. Normalization techniques ensure that metabolite concentrations are comparable across samples (Bongaerts et al., 2020). Specialized software tools and databases, such as MetaboAnalyst and Human Metabolome Database (HMDB), are used for the identification and quantification of metabolites. Accurate identification often requires matching mass spectra against reference libraries (Wishart et al., 2018). Statistical methods, including multivariate analysis (e.g., PCA, PLS-DA), are used to identify patterns and differences in metabolite profiles. Pathway analysis tools, like KEGG and MetaboAnalyst, help in understanding the biological relevance of these metabolites by mapping them to metabolic pathways (Chen et al., 2021).

Recent advances in metabolomics have greatly enhanced our understanding of the gut microbiome's role in health and disease. For example, metabolomics has identified specific microbial metabolites, such as short-chain fatty acids (SCFAs), which play crucial roles in gut health by modulating inflammation and energy metabolism (O'Riordan et al., 2022).

Studies have shown that the gut microbiome's metabolic output can influence host metabolic disorders, such as obesity and diabetes. Metabolomic profiling has revealed distinct metabolic signatures associated with these conditions, suggesting potential biomarkers for diagnosis and targets for therapeutic intervention (Lucarelli et al., 2019).

Moreover, metabolomics is instrumental in understanding the effects of diet on the gut microbiome. Dietary components can alter the production of metabolites, impacting host health. For instance, high-fiber diets increase the production of beneficial SCFAs, while high-fat diets are associated with metabolites linked to adverse health effects (Blaak et al., 2020).

Integration of metabolomics with other omics technologies, such as genomics and proteomics, provides a comprehensive view of the gut microbiome's functionality and its interactions with the host. This holistic approach is crucial for developing personalized nutrition and precision medicine strategies aimed at improving health outcomes (Gray et al., 2020).

Single-Cell Sequencing

Single-cell sequencing allows detailed analysis of individual microbial cells, revealing their genetic makeup and functional capabilities. This approach is particularly useful for studying rare or uncultivable microbes within the gut, providing a high-resolution understanding of microbial diversity and function that bulk sequencing methods cannot achieve.

To realise this technic some technical aspects are necessary; Isolation of Single Cells (Microfluidics: Microfluidic devices enable the isolation and manipulation of single cells by capturing them in tiny droplets or wells). This method provides high throughput and precise control, making it ideal for handling complex microbial communities (Yu et al., 2022). Fluorescence-Activated Cell Sorting (FACS): FACS sorts individual cells based on fluorescent markers. This technique is often used to enrich specific microbial populations from mixed samples (Reichart et al., 2020). Laser Capture Microdissection (LCM): LCM isolates single cells from tissue sections using a laser. This method is particularly useful for studying the spatial distribution of microbes in the gut (Espina et al., 2007). Amplification and Sequencing (Whole Genome Amplification (WGA): Because single cells contain limited DNA, WGA techniques such as multiple displacement amplification (MDA) are used to amplify the genetic material before sequencing. MDA offers high fidelity and uniform coverage, essential for accurate genomic analysis (Long et al., 2020). Single-Cell RNA Sequencing (scRNA-seq): scRNA-seq profiles gene expression at the single-cell level, providing insights into the functional states of individual microbes. Techniques like Smart-seq2 and Drop-seq are commonly used for this purpose (Huang et al., 2024). Data Analysis (Assembly and Annotation: Sequencing data from single cells are assembled into complete or near-complete genomes. Bioinformatics tools are used to annotate genes and predict functional capabilities (Davis et al., 2020). Integration with Other Omics Data: Integrating single-cell sequencing data with metagenomics, metabolomics, and proteomics provides a comprehensive view of microbial ecology and function. This holistic approach helps in understanding the interactions between different microbial species and their impact on the host (Cheng et al., 2019).

Single-cell sequencing has significantly advanced our understanding of the gut microbiome. For instance, this technique has uncovered novel microbial species and functions that were previously undetectable using traditional methods. It has revealed the presence of rare and uncultivable microbes, shedding light on their roles in health and disease (Brown et al., 2016).

One notable application of single-cell sequencing is in studying antibiotic resistance. By analyzing individual cells, researchers can identify resistance genes and their mechanisms, providing insights into how resistance spreads within microbial communities (Li et al., 2023).

Single-cell sequencing has revolutionized our understanding of the gut-brain axis by allowing researchers to dissect the complex interactions between individual microbial cells and host neurons. A notable example is a study where single-cell RNA sequencing was employed to identify specific gut bacteria that produce metabolites influencing serotonin production in the gut, a key neurotransmitter involved in mood regulation and brain function (Tan et al., 2024). This discovery highlighted potential microbial targets for treating disorders such as depression and anxiety.

Furthermore, single-cell sequencing has been integrated into studies examining how individual gut microbes contribute to neuroinflammation, which is implicated in neurodegenerative diseases like Parkinson's and Alzheimer's. For instance, researchers have used this technology to profile microglia—the brain's resident immune cells—and their interaction with gut-derived microbial metabolites, uncovering mechanisms through which gut dysbiosis might contribute to neurodegeneration (Palma, 2024).

In personalized medicine, single-cell sequencing enables a granular view of the gut microbiome at an individual level. By characterizing the gene expression profiles of specific microbial populations in a patient's gut, clinicians can tailor dietary recommendations or probiotic treatments to optimize gut health and, consequently, improve overall well-being. For example, in a study involving patients with irritable bowel syndrome (IBS), single-cell sequencing was used to identify microbial shifts associated with symptoms, leading to more targeted probiotic therapies (Seo & Song, 2024).

Bioinformatics

Bioinformatics tools are essential for analyzing and interpreting the vast amounts of data generated by high-throughput sequencing techniques. These tools facilitate the identification of microbial species, functional genes, and metabolic pathways, and play a critical role in understanding the complex interactions within the gut microbiome.

Data preprocessing includes quality control measures such as removing low-quality reads and contaminants using tools like FastQC (Pérez-Rubio et al., 2019) and Trimmomatic (Bolger et al., 2014). Sequence alignment to reference genomes or databases is achieved through tools like BWA (Clausen et al., 2018) and Bowtie2 (Musich et al., 2021), which are crucial for identifying microbial species and detecting genetic variations.

For taxonomic classification, metagenomic profiling tools such as Kraken2 (Lu et al., 2022) and MetaPhlAn3 (Beghini et al., 2021) are employed to classify metagenomic sequences into taxonomic groups, providing insights into the microbial composition of samples. Phylogenetic analysis tools like MEGA (Keklik, 2023) and RAxML (Edler et al., 2021) construct phylogenetic trees to study evolutionary relationships among microbial species.

Gene prediction tools such as Prodigal (Silva et al., 2021) identify potential genes in metagenomic sequences, which can be functionally annotated using databases like KEGG and COG (Maranga et al., 2023). Pathway analysis tools like HUMAnN3 (Maranga et al., 2023) map genes to metabolic pathways, elucidating the functional capabilities of the microbiome.

Microbial interaction networks are inferred through co-occurrence network analysis using tools like CoNet and SparCC (Yousefi et al., 2023). Visualization tools such as Cytoscape (Alzahrani & Fernstad, 2023) graphically represent microbial interaction networks, facilitating the exploration of complex relationships.

Multi-omics integration tools like iClusterPlus and MOFA+ (Subramanian et al., 2020) combine metagenomics with transcriptomics, proteomics, and metabolomics data, offering a holistic view of microbial functions and host interactions. Data repositories such as the Human Microbiome Project

(HMP) and MG-RAST (Keegan et al., 2016) provide access to large-scale microbiome datasets, enabling comparative analyses and validation of findings.

Recent advances in bioinformatics have significantly enhanced our ability to study the gut microbiome. The development of more accurate and efficient algorithms for metagenomic assembly and binning has improved the reconstruction of microbial genomes from complex samples (Yang et al., 2021). Machine learning approaches are increasingly being applied to predict microbial functions and interactions from multi-omics data (McElhinney et al., 2022). Bioinformatics tools are crucial for identifying biomarkers associated with diseases. Microbial signatures identified through metagenomic and metabolomic analyses have been linked to conditions such as inflammatory bowel disease (IBD) and colorectal cancer (Al-Mustanjid et al., 2020). These biomarkers can potentially be used for early diagnosis and personalized treatment strategies. Bioinformatics has facilitated the exploration of the gut-brain axis. By integrating metagenomic and transcriptomic data, researchers have identified microbial genes and metabolites that influence brain function and behavior, shedding light on the microbial basis of neuropsychiatric disorders (Liu et al., 2024).

Physiological Impacts of the Gut Microbiome

Digestion and Nutrient Absorption

The gut microbiome plays a crucial role in digesting complex carbohydrates and fiber, producing short-chain fatty acids (SCFAs) that are vital for colon health and energy metabolism. The digestion of complex carbohydrates, which are not broken down by human digestive enzymes, relies heavily on microbial enzymes. Bacteroides and Firmicutes, prominent members of the gut microbiome, possess the necessary enzymes to degrade these carbohydrates into simpler molecules that can be absorbed by the host (Cockburn & Koropatkin, 2016).

SCFAs such as acetate, propionate, and butyrate are the primary metabolites produced during the fermentation of dietary fibers by gut bacteria. These SCFAs serve multiple functions: they provide an energy source for colonocytes, help maintain the integrity of the gut barrier, and have systemic effects on metabolism and inflammation (Liu et al., 2021). Butyrate, in particular, is essential for colon health as it fuels the cells lining the colon and has anti-inflammatory properties (Canani et al., 2011).

Furthermore, the gut microbiome synthesizes essential vitamins, such as vitamin K and certain B vitamins, which play critical roles in blood coagulation and cellular metabolism, respectively (Pham et al., 2021). The production of these vitamins is another testament to the symbiotic relationship between humans and their gut microbiota.

Recent studies have also highlighted the impact of the gut microbiome on lipid metabolism. Gut bacteria can influence the host's lipid profile by modulating the bile acid pool, which in turn affects lipid absorption and cholesterol metabolism (Molinero et al., 2019). This interaction underscores the complexity of the gut microbiome's role in nutrient absorption and metabolism.

Emerging research continues to uncover the intricate connections between the gut microbiome and various aspects of host physiology. For example, recent findings suggest that specific gut microbial communities are associated with improved metabolic health and reduced risk of conditions such as obesity and type 2 diabetes (Fan & Pedersen, 2021). Moreover, dietary interventions that promote the growth of beneficial microbes are being explored as potential therapeutic strategies to enhance nutrient absorption and metabolic health (Yang et al., 2020).

Metabolism and Energy Balance

Gut microbiota are integral to regulating host metabolism and energy balance. They influence various physiological processes including fat storage, glucose homeostasis, and overall metabolic health. Recent advancements in microbiome research have provided deeper insights into these interactions, revealing the significant role of gut microbes in metabolic disorders such as obesity and diabetes.

Gut microbiota modulates fat metabolism through several mechanisms. Microbes assist in digesting and fermenting dietary fibers, producing short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate, which impact lipid metabolism. Increased SCFA production has been associated with enhanced fat oxidation and reduced adiposity (May & Den Hartigh, 2021). Specific gut bacteria, such as those from the Firmicutes phylum, can influence energy extraction from the diet and promote fat accumulation (Amabebe et al., 2020).

The microbiome plays a role in regulating glucose metabolism and insulin sensitivity. SCFAs, particularly butyrate, have been shown to improve insulin sensitivity and modulate glucose homeostasis (Van der Hee & Wells 2021). Dysbiosis, characterized by an imbalance in microbial communities, can impair glucose tolerance and contribute to insulin resistance. For example, a reduction in beneficial bacteria like *Akkermansia muciniphila* has been linked to metabolic syndrome and type 2 diabetes (Ji-Chao et al., 2019).

Dysbiosis has been increasingly associated with metabolic disorders, including obesity and type 2 diabetes. Imbalances in microbial composition can lead to chronic inflammation and disrupt metabolic pathways. A decrease in microbial diversity and an imbalance in the Firmicutes/Bacteroidetes ratio have been linked to obesity (Magne et al., 2020). Meta-analyses confirm that gut microbiota alterations are strongly associated with metabolic disorders (Li et al., 2021).

High-throughput sequencing and advanced analytical techniques have improved our understanding of the gut microbiome's role in metabolism. Metagenomics and metabolomics studies have identified key microbial species and their metabolites involved in metabolic regulation. Probiotics and prebiotics are being investigated as potential interventions to restore microbial balance and improve metabolic health. Clinical trials are exploring the efficacy of microbiome-targeted therapies for managing obesity and diabetes (Green et al., 2020).

Gut microbiota impact energy harvest from the diet and fat storage through various mechanisms. Microbes ferment dietary fibers into SCFAs, such as acetate, propionate, and butyrate. These SCFAs are absorbed and used for energy, influencing caloric intake and fat accumulation (May & Den Hartigh, 2021). An increased abundance of Firmicutes relative to Bacteroidetes has been associated with greater energy absorption and fat accumulation (Wang et al., 2020). SCFAs also modulate the expression of genes involved in fat metabolism and storage, such as adipogenesis and lipolysis (Van der Hee & Wells 2021).

Gut microbiota affect systemic inflammation and insulin sensitivity, both crucial in obesity development. Dysbiosis can lead to increased intestinal permeability and systemic inflammation, disrupting insulin signaling and contributing to insulin resistance (Aron-Wisniewsky et al., 2021; Blaser & Falkow, 2009).

Gut bacteria influence the secretion of hormones involved in appetite regulation and energy expenditure. For example, certain bacteria can affect the levels of hormones such as leptin and ghrelin, which regulate hunger and satiety (Schalla & Stengel, 2020). Microbial metabolites can influence the release of these hormones, impacting feeding behavior and weight gain.

Recent studies have linked gut microbiome composition to obesity. High-throughput sequencing and metagenomic analyses have identified microbial communities associated with obesity and metabolic disorders. Individuals with obesity often have a lower diversity of gut microbiota and different bacterial taxa compared to lean individuals (Duan et al., 2021). An increased Firmicutes-to-Bacteroidetes ratio is often observed in obese individuals (Stojanov et al., 2020). Germ-free and microbiota transplantation models have demonstrated that transferring gut microbiota from obese individuals to germ-free mice can induce obesity, supporting the microbiome's causal role in obesity (Dalby, 2023).

Longitudinal studies have linked changes in gut microbiota to weight gain and obesity over time. Changes in microbiome diversity have been predictive of weight gain in healthy individuals (Bischoff et al., 2022). Clinical trials have explored the impact of probiotic and prebiotic interventions on weight management, with varying results indicating potential benefits in modifying gut microbiota for obesity management (Vallianou et al., 2020).

Modifying the gut microbiome through probiotics and prebiotics has emerged as a potential strategy for obesity prevention and treatment. Probiotics, live microorganisms administered in adequate amounts, can provide health benefits and influence weight and fat mass by altering the gut microbiome (Fan & Pedersen, 2021). Prebiotics, dietary fibers that promote beneficial bacteria growth, can affect weight management by improving microbial diversity and function (Rezende et al., 2021).

Dietary modifications can influence the gut microbiome and, consequently, obesity. Diets rich in fiber, polyphenols, and fermented foods can positively impact microbial composition and metabolic health. Fiber-rich diets have been associated with increased SCFA production and reduced fat accumulation

(Iversen et al., 2022). Personalized dietary approaches considering individual microbiome profiles may offer more effective weight management strategies.

Fecal microbiota transplantation (FMT), involving transferring gut microbiota from a healthy donor to an individual with obesity, has shown promise. FMT can restore microbial diversity and function, potentially leading to weight loss and improved metabolic health (Zikou et al., 2024). However, more research is needed to understand the long-term effects and safety of FMT for obesity treatment.

Cardiovascular Health

The gut microbiome has emerged as a critical player in cardiovascular health, influencing various aspects of cardiovascular disease (CVD) risk through complex interactions with metabolic and inflammatory pathways. The gut microbiota's impact on cardiovascular health is mediated through several mechanisms, including modulation of lipid metabolism, inflammation, and the production of bioactive metabolites.

The gut microbiome can influence lipid metabolism by affecting the absorption and metabolism of dietary fats. Microbes in the gut produce metabolites like trimethylamine (TMA) from dietary choline, carnitine, and betaine. TMA is converted to trimethylamine N-oxide (TMAO) in the liver, which has been implicated in promoting atherosclerosis and cardiovascular disease. Elevated levels of TMAO are associated with an increased risk of coronary artery disease (Witkowski et al., 2020).

Chronic low-grade inflammation is a key factor in cardiovascular disease. Dysbiosis, or an imbalance in the gut microbiota, can lead to increased intestinal permeability and the translocation of bacterial endotoxins into the bloodstream, which contributes to systemic inflammation. This inflammation can exacerbate conditions such as atherosclerosis and hypertension (Cani et al., 2007).

Recent studies suggest that gut microbiota can influence blood pressure. Gut bacteria may affect the renin-angiotensin system (RAS), which plays a crucial role in regulating blood pressure. For instance, certain microbial metabolites can modulate RAS activity, potentially influencing hypertension development (Ting et al., 2022).

Gut microbiota can impact cholesterol metabolism by altering the synthesis and excretion of bile acids. Microbes convert primary bile acids into secondary bile acids, which influence cholesterol homeostasis. A disrupted bile acid metabolism is associated with altered cholesterol levels and cardiovascular risk (Einarsson et al., 1991; Ruan et al., 2020).

Studies have shown that the composition of the gut microbiome can be associated with cardiovascular risk factors. For example, a lower diversity of gut microbiota and alterations in specific bacterial taxa have been linked to increased cardiovascular risk (Toya et al., 2020). High-throughput sequencing studies have identified distinct microbial signatures associated with conditions such as atherosclerosis and hypertension.

Clinical trials investigating the impact of probiotics and prebiotics on cardiovascular health have shown mixed results. Some studies suggest potential benefits of certain probiotic strains in reducing blood pressure and improving lipid profiles (Wu & Chiou, 2021). Observational studies have linked alterations in gut microbiota with cardiovascular disease outcomes, supporting the role of the microbiome in cardiovascular health (Witkowski et al., 2020).

Diet plays a significant role in shaping the gut microbiome and, consequently, cardiovascular health. Diets high in fiber, polyphenols, and fermented foods can positively influence microbiome composition and reduce cardiovascular risk. For example, dietary fiber can promote the growth of beneficial bacteria and improve lipid profiles (Van der Hee & Wells 2021).

Probiotics and prebiotics have potential as therapeutic interventions for cardiovascular health. Certain probiotic strains have shown promise in improving cholesterol levels and reducing blood pressure (Wu & Chiou, 2021). Prebiotics that enhance the growth of beneficial gut bacteria may also have cardiovascular benefits (Wu & Chiou, 2021).

Although still an emerging area, FMT has shown potential in modulating the gut microbiome to influence cardiovascular health. Research into the effects of FMT on cardiovascular risk factors is ongoing, with preliminary studies indicating possible benefits in improving metabolic profiles (Fan et al., 2022).

Role of the Intestinal Microbiome in Sterility

The intestinal microbiome, comprising trillions of microorganisms residing in the gastrointestinal tract, plays a crucial role in overall health, including reproductive health. Emerging research suggests that the gut microbiome may influence sterility or fertility through several mechanisms ; Sex Hormone Metabolism: The gut microbiome can impact the metabolism of sex hormones such as estrogen and testosterone. Certain gut bacteria produce enzymes that modify these hormones, influencing their levels and activity in the body. For instance, the enzyme β -glucuronidase, produced by some gut bacteria, can deconjugate estrogens in the gut, affecting their recirculation and activity (Ervin et al., 2019). Imbalances in these processes may contribute to reproductive issues, Influence on Hormonal Balance: Dysbiosis, or an imbalance in the gut microbiome, can disrupt the hormonal balance necessary for normal reproductive function. This can affect ovulation, menstrual cycles, and sperm production, potentially leading to sterility (Wang et al., 2024).

Recent studies have shown that women with conditions such as polycystic ovary syndrome (PCOS) often exhibit gut dysbiosis. This imbalance may contribute to the hormonal and metabolic disturbances seen in PCOS, affecting fertility (He & Li, 2020).

Research has indicated that the gut microbiome may also influence male fertility. Gut bacteria can affect testosterone levels and sperm quality. Dysbiosis has been linked to reduced sperm motility and concentration (Venneri et al., 2022).

Depending on what has been mentioned certain solutions can be proposed; supplementing with probiotics and prebiotics can help restore a healthy gut microbiome balance. This may improve hormonal balance, reduce inflammation, and enhance nutrient absorption, potentially improving fertility outcomes (Rani et al., 2023). A diet rich in fiber, fruits, vegetables, and fermented foods can promote a healthy gut microbiome. Avoiding processed foods and sugars that contribute to dysbiosis can also be beneficial (Arnone et al., 2022). FMT is being explored as a potential treatment for severe dysbiosis. By transplanting healthy gut microbiota, this procedure aims to restore microbial balance and improve overall health, including reproductive health (Camarrota et al., 2017).

Microbiome and Sex Determination

Research into the influence of the gut microbiome on sex determination is still in its early stages. However, there are hypotheses and preliminary findings suggesting that the microbiome may play a role in the regulation of sex hormones and secondary sexual characteristics. For instance, the gut microbiome can influence the metabolism of sex hormones such as estrogen and testosterone through the production of microbial metabolites (Hussain et al., 2021).

Studies have shown that the gut microbiome can exhibit sex-dependent differences in composition and function. These differences may be influenced by sex hormones and could potentially impact sex-specific health outcomes. For example, certain microbial taxa have been found to be differentially abundant in males and females (Medjaoui et al., 2016), which could influence immune responses and susceptibility to diseases (Zheng et al., 2020).

Recent studies suggest that gut microbiota can impact the metabolism of sex hormones. For example, specific gut bacteria are involved in the conversion of estrogens into their more active or inactive forms, affecting hormonal balance. This could have implications for sexual development and reproductive health (He et al., 2021).

There is growing interest in understanding how early-life microbiome composition affects developmental outcomes. Studies have indicated that disruptions in the microbiome during critical periods of development may influence sexual maturation and health later in life. Research in animal models has shown that microbiome composition can affect puberty onset and reproductive health (Sisk-Hackworth et al., 2023).

Probiotic interventions and dietary modifications aimed at promoting a healthy microbiome might influence developmental outcomes. For example, ensuring a balanced microbiome through early-life probiotics might support overall health and development, potentially influencing sex-specific health outcomes (Snigdha et al., 2022).

More research is needed to fully understand the mechanisms by which the gut microbiome might influence sex determination and development. Longitudinal studies and clinical trials will be crucial for elucidating these relationships and for developing targeted interventions.

Immune System Modulation

The gut microbiome is integral to the development and function of the immune system. Microbial interactions with immune cells in the gut mucosa play a crucial role in maintaining immune homeostasis and protecting against pathogens. The relationship between the gut microbiome and the immune system is bidirectional, with the microbiome influencing immune responses and, conversely, immune responses shaping microbiome composition.

Immunological Impacts of the Gut Microbiome

The gut microbiome is crucial in shaping the development of the immune system, particularly in early life. Microbial exposure influences the maturation of immune cells and the development of mucosal immunity. For instance, exposure to diverse microbial communities helps train the immune system to distinguish between pathogenic and non-pathogenic entities. Germ-free mice, which lack a gut microbiome, show impaired development of mucosal immunity and altered immune cell populations compared to conventionally raised mice (Thomson et al., 2022).

Gut microbiota modulate systemic immune responses through various mechanisms. Microbial-derived metabolites, such as short-chain fatty acids (SCFAs), play a role in maintaining immune homeostasis. SCFAs, particularly butyrate, influence the differentiation and function of regulatory T cells (Tregs), which are essential for controlling immune responses and preventing excessive inflammation (Kim, 2021).

The gut microbiome helps maintain the integrity of the intestinal barrier. A healthy microbiome supports the production of mucins and antimicrobial peptides that protect against pathogen invasion. Dysbiosis can compromise the intestinal barrier, leading to increased intestinal permeability, which allows microbial components to enter systemic circulation and trigger inflammation (Li et al., 2016).

Autoimmune Diseases

The gut microbiome has been linked to the development and progression of various autoimmune diseases. Dysbiosis, characterized by an imbalance in microbial communities, can contribute to autoimmune disease pathogenesis through several mechanisms (Molecular Mimicry: Some gut bacteria may produce antigens that resemble self-antigens, leading to cross-reactivity and autoimmune responses. For example, *Helicobacter pylori* has been implicated in the pathogenesis of autoimmune gastritis (Lenti et al., 2020), Immune Activation: Dysbiosis can lead to aberrant immune activation and the production of autoantibodies. For instance, in systemic lupus erythematosus (SLE), alterations in gut microbiota have been associated with increased levels of pro-inflammatory cytokines and autoantibodies (Miyauchi et al., 2023), Intestinal Permeability: Increased intestinal permeability due to dysbiosis can allow the entry of microbial products into the bloodstream, potentially triggering systemic inflammation and autoimmunity (Cani et Delzenne, 2008).

Emerging research has identified specific microbial taxa and metabolites associated with autoimmune diseases. For instance, studies have shown that patients with rheumatoid arthritis (RA) exhibit altered gut microbiota composition compared to healthy controls (Chen et al., 2021). Inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, have also been linked to dysbiosis and changes in microbial diversity (Alam et al., 2020).

Therapeutic strategies targeting the gut microbiome are being explored for managing autoimmune diseases. Probiotics and prebiotics have shown promise in modulating the immune system and reducing inflammation in some autoimmune conditions (Roy & Dhaneshwar, 2023). Fecal microbiota transplantation (FMT) is also being investigated for its potential to restore microbial balance and alleviate autoimmune symptoms (Fan & Pedersen, 2021).

Mental Health and Neurological Function

Emerging research highlights the gut-brain axis, where gut microbes influence neurological function and behavior through the production of neurotransmitters and modulation of the immune system. For example, specific gut bacteria can produce neurotransmitters like serotonin, which play a crucial role in

regulating mood and cognitive functions. Additionally, the gut microbiome can modulate systemic inflammation, which is linked to various neuropsychiatric disorders (Mitrea et al., 2022).

Mental Health

The gut microbiome significantly influences mood disorders and cognitive functions. Recent studies have demonstrated that dysbiosis, or an imbalance in gut microbiota, is associated with conditions such as depression, anxiety, and even schizophrenia.

For instance, a study in 2023 found that probiotic supplementation could reduce depressive symptoms by modulating gut bacteria composition. This study indicated that certain probiotic strains could enhance the production of gamma-aminobutyric acid (GABA), a neurotransmitter that helps regulate mood and anxiety levels (Chudzik et al., 2021).

Moreover, gut microbiota have been linked to the regulation of the stress response. Chronic stress can alter gut microbiota composition, leading to increased intestinal permeability and systemic inflammation, which may contribute to the development of mood disorders. A review by Dinan and Cryan (2017) highlighted that stress-induced changes in the gut microbiome could exacerbate inflammation and affect the hypothalamic-pituitary-adrenal (HPA) axis, influencing mood and anxiety levels (Dinan & Cryan, 2017).

Additionally, a study published in 2024 showed that gut bacteria could influence the production of brain-derived neurotrophic factor (BDNF), a protein crucial for brain health and plasticity, suggesting that the microbiome's role in mental health extends beyond neurotransmitter production to broader neurobiological processes. This study found that gut microbiota modulation could enhance BDNF expression in the hippocampus, an area of the brain associated with mood regulation and cognitive function (Molska et al., 2024).

Another 2020 study explored the relationship between gut microbiota and neuroinflammation, finding that certain gut bacteria could produce metabolites that influence neuroinflammatory pathways, potentially affecting mental health. These findings suggest that gut microbiota modulation could be a therapeutic target for reducing neuroinflammation in psychiatric disorders (Carlessi et al., 2021).

Furthermore, research has shown that the gut microbiome can influence the synthesis and availability of other key neurotransmitters such as serotonin and dopamine. For example, a 2021 study revealed that microbial-derived short-chain fatty acids (SCFAs) could impact the synthesis of serotonin in the gut, which then affects mood and behavior (Gomaa, 2020).

Collectively, these studies underscore the significant role of the gut microbiome in mental health and highlight the potential for microbiome-targeted therapies to alleviate symptoms of mood disorders and improve cognitive functions.

Gut-Brain Axis

The gut-brain axis encompasses complex and bidirectional communication pathways that involve neural, hormonal, and immune mechanisms. Central to this communication is the vagus nerve, which serves as a major conduit for signals traveling between the gut and the brain. This nerve transmits information that can influence brain function and behavior, underscoring the importance of gut health for overall mental well-being (Cryan & Dinan, 2012).

Microbial metabolites such as short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, play crucial roles in this communication. These SCFAs, produced during the fermentation of dietary fibers by gut bacteria, can cross the blood-brain barrier and influence brain health. For instance, butyrate has been shown to have anti-inflammatory effects and can modulate the production of brain-derived neurotrophic factor (BDNF), which is essential for brain plasticity and cognitive function (Alpino et al., 2024).

Recent research has also explored how psychotropic medications, such as antidepressants, can alter the gut microbiota composition. This alteration can impact the efficacy and side effects of these medications. A study by Zhang et al. (2021) demonstrated that fluoxetine, a commonly prescribed antidepressant, can modify the gut microbiome in ways that influence depressive-like behaviors in animal models. These findings suggest a potential microbial endocrinology-based mechanism of action, where the gut microbiota modulates the effectiveness of psychiatric treatments (Zhang et al., 2021).

Furthermore, emerging studies are investigating the impact of gut microbiota on neurodevelopmental disorders such as autism spectrum disorder (ASD). A study by Eicher and Mohajeri (2022) found that specific gut bacteria might influence the severity of ASD symptoms by modulating immune and metabolic pathways. These bacteria can affect the production of neurotransmitters and neuroactive compounds, which in turn impact brain development and function (Eicher & Mohajeri, 2022).

Another area of research focuses on the role of the gut microbiome in neuroinflammation. Chronic neuroinflammation is linked to various psychiatric and neurodegenerative disorders. Microbial metabolites, particularly SCFAs, have been shown to influence the activation of microglia, the brain's resident immune cells. By modulating microglial activity, the gut microbiome can impact neuroinflammatory processes and potentially alleviate symptoms of mental health disorders (Carlessi et al., 2021).

Additionally, the gut microbiome influences the synthesis and availability of key neurotransmitters such as serotonin, dopamine, and GABA. For example, gut bacteria produce precursors to serotonin, which can then be utilized by the host to produce this crucial neurotransmitter. Serotonin produced in the gut is involved in regulating mood, appetite, and sleep, highlighting the microbiome's role in maintaining mental health (Margooob et al., 2024).

Evolution of the Human Gut Microbiome

Historical Perspective

The human gut microbiome has evolved significantly over time, shaped by diet, lifestyle, and environmental changes. Early humans, who were hunter-gatherers, had a diverse microbiome due to a varied diet rich in fibrous plants, wild meats, and seasonal foods. This diversity is evidenced by studies of ancient human feces, or coprolites, which show a high abundance of fiber-degrading bacteria and diverse microbial communities (Blaser & Falkow, 2009).

The transition to agriculture around 10,000 years ago marked a significant shift in the human diet to include more grains and domesticated animal products. This change led to adaptations in the gut microbiome, including an increase in bacteria capable of fermenting carbohydrates. Analysis of ancient dental calculus reveals shifts in oral microbiota corresponding to dietary transitions (Adler et al., 2013).

The Industrial Revolution brought about further changes with the introduction of processed foods, refined sugars, and increased hygiene practices. These changes have been linked to a decline in microbial diversity, correlating with the rise of chronic diseases (Clemente et al., 2015). Modern urban populations tend to have a less diverse microbiome compared to rural and traditional societies (Sánchez-Quinto et al., 2020).

Influence of Lifestyle Changes

Modern lifestyle factors, such as diet, antibiotic use, and reduced physical activity, have significantly impacted the gut microbiome. Diets high in fat and low in fiber, typical of industrialized countries, are associated with a reduction in beneficial microbial species and an increase in bacteria linked to obesity and metabolic disorders (Conlon & Bird, 2014).

Antibiotic use, while essential for treating infections, can disrupt gut microbial communities, leading to long-term health effects. Even short courses of antibiotics can reduce microbial diversity and promote the growth of resistant strains (Uddin et al., 2021). Increased sanitation and reduced exposure to natural environments have limited our contact with diverse microbial populations, affecting immune system development and potentially contributing to autoimmune diseases (Khan & Wang, 2020).

Comparative studies highlight differences between traditional and industrialized populations. For example, the Hadza people of Tanzania, who maintain a hunter-gatherer lifestyle, possess a gut microbiome with higher diversity and distinct microbial taxa compared to urban dwellers (Fragiadakis et al., 2019).

Comparative Studies

Comparative analyses between ancient and modern human microbiomes reveal the impact of lifestyle changes on gut microbial communities. Studies on ancient fecal samples from mummies and other archaeological sites show that ancient humans had more diverse and balanced microbiomes (Rifkin et al., 2020).

Modern humans, particularly those in industrialized societies, exhibit reduced microbial diversity. For instance, research comparing the microbiomes of the Yanomami people, an isolated Amazonian tribe, with those of urban Americans found significantly higher microbial diversity in the Yanomami (Clemente et al., 2015).

These differences have significant health implications. Reduced microbial diversity is associated with higher risks of various diseases, including obesity, diabetes, and inflammatory bowel disease (IBD) (Ghosh & Pramanik, 2021). Understanding these changes can inform interventions to restore microbial diversity and improve health outcomes.

Ethnic Differences in the Gut Microbiome

Variations Across Populations

Studies have highlighted substantial variations in gut microbiome composition across different ethnic groups, influenced by diet, lifestyle, and geographical location. Research shows that Western populations typically have lower microbial diversity compared to rural communities in Africa and South America, where diets are richer in fiber and plant-based foods (Deschasaux et al., 2018).

Specific microbial taxa also differ between populations. A study comparing individuals from the USA, Malawi, and Amerindian populations in Venezuela found distinct microbial compositions linked to dietary habits and environmental exposures (Gupta et al., 2017). Another recent study found that gut microbiota compositions varied significantly between urban and rural populations in China, with rural populations having higher microbial diversity due to their fiber-rich diet (Um et al., 2023).

Genetic and Environmental Factors

Genetic factors contribute to the gut microbiome's composition, but environmental influences such as diet and lifestyle are more substantial. Host genetics can affect the abundance and diversity of specific microbial species. For example, twin studies have shown that identical twins have more similar gut microbiomes compared to fraternal twins, suggesting a genetic component (Williams et al., 2022).

However, environmental factors, including diet, antibiotic usage, and microbial exposure, profoundly impact the gut microbiome. Diet is a major determinant, with high-fiber diets promoting a diverse microbiome rich in beneficial bacteria, while Western diets high in fats and sugars can reduce microbial diversity (Moszak et al., 2020).

Cultural practices and geographic location also influence the gut microbiome. A study comparing urban and rural populations in China found significant differences linked to dietary habits and sanitation practices, with rural populations having higher prevalence of bacteria associated with fiber fermentation (Sun et al., 2021). Another recent study demonstrated that the gut microbiomes of African Americans are distinct from those of other American populations, reflecting differences in diet and lifestyle (Borrello et al., 2022).

Therapeutic Potential of the Gut Microbiome

Probiotics

Probiotics are live microorganisms that, when administered in adequate amounts, provide health benefits to the host. They are commonly used to restore microbial balance and address various gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and antibiotic-associated diarrhea. Probiotics have been shown to enhance gut barrier function, modulate the immune system, and inhibit pathogenic bacteria (Gou et al., 2022).

Recent research has explored the role of probiotics in mental health, with evidence suggesting they can alleviate symptoms of depression and anxiety by modulating the gut-brain axis. A meta-analysis found that probiotic supplementation significantly reduced depressive symptoms in adults (Musazadeh et al., 2023).

Prebiotics

Prebiotics are non-digestible food components that promote the growth of beneficial gut bacteria. They are typically found in foods such as garlic, onions, bananas, and whole grains. Prebiotics enhance gut health by selectively stimulating the proliferation of beneficial microbes, such as Bifidobacteria and

Lactobacilli, which produce short-chain fatty acids (SCFAs) that nourish the gut lining and support immune function (Keerthi et al., 2021).

Recent studies have shown that prebiotics can improve metabolic health, enhance mineral absorption, and reduce the risk of colorectal cancer (Peredo-Lovillo et al., 2020). Additionally, a 2022 study highlighted the role of prebiotics in modulating the gut microbiome to improve sleep quality and cognitive function (Haarhuis et al., 2022).

Fecal Microbiota Transplantation (FMT)

FMT involves transferring stool from a healthy donor to a patient with dysbiosis to restore a healthy microbial community. This therapy has shown significant promise in treating conditions such as *Clostridium difficile* infection (CDI), which can be refractory to conventional antibiotic treatments. FMT has also been explored for its potential in treating inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and even metabolic disorders (Camarota et al., 2017).

Recent research suggests that FMT could modulate the immune system and restore gut microbiome diversity, leading to sustained clinical remission in some patients with IBD. A 2021 study demonstrated the long-term effectiveness of FMT in maintaining remission in ulcerative colitis patients (Crothers et al., 2021).

Personalized Medicine

Advancements in microbiome research are paving the way for personalized medicine, where therapeutic interventions are tailored to an individual's unique microbial profile. The integration of metagenomics, metabolomics, and microbiome sequencing allows for a deeper understanding of the complex interactions between the host and their microbiome. Personalized approaches could optimize treatments for conditions such as obesity, diabetes, and mental health disorders by targeting specific microbial imbalances (Aziz et al., 2023).

For instance, personalized dietary recommendations based on microbiome composition have been shown to improve glycemic control in individuals with prediabetes. A 2022 study found that such tailored interventions led to significant improvements in metabolic health markers compared to generic dietary advice (Hillesheim & Brennan, 2023).

Role of Birth Type and Lactation in the Composition of the Intestinal Microbiome

The mode of birth delivery and breastfeeding play crucial roles in the initial colonization and development of the infant gut microbiome. Vaginally delivered infants are exposed to their mother's vaginal and fecal microbiota, which promotes the colonization of beneficial bacteria such as *Lactobacillus* and *Bifidobacterium* (Dominguez-Bello et al., 2010). In contrast, cesarean-delivered infants often have a delayed and less diverse microbiome, initially resembling skin microbiota, which may increase their risk for certain immune-related conditions (Medjaoui et al., 2016).

Breastfeeding further shapes the infant gut microbiome by providing human milk oligosaccharides (HMOs) that selectively feed beneficial bacteria like *Bifidobacteria*. These bacteria help in the digestion of HMOs, enhance gut barrier function, and modulate the immune system, offering protection against pathogens (Bode, 2012). Recent studies have shown that breastfeeding can have long-term effects on the gut microbiome and overall health, potentially reducing the risk of obesity, allergies, and autoimmune diseases (Sarkar et al., 2021).

Future Research Directions

Understanding Microbial Interactions

Future research should focus on understanding the complex interactions between different microbial species and their collective impact on host health. Investigating how beneficial microorganisms interact with potentially harmful ones and how these dynamics influence health outcomes is crucial. For example, Machado et al., (2021) discuss the need for deeper exploration of microbial networks and their implications for health, highlighting the importance of understanding these complex interactions (Machado et al., 2021).

Exploring the formation of microbial networks, where species influence each other's growth and metabolic activities, is also important. Rebersek (2021) highlight how microbial interactions contribute

to colorectal cancer, underscoring the significance of understanding these networks and their potential impact on health (Rebersek, 2021).

Additionally, understanding how microbial communities maintain stability and respond to disturbances such as antibiotic use, dietary changes, or infections is essential. Examining how host factors like immune responses or genetic predispositions affect microbial interactions and vice versa will further illuminate these dynamics.

Longitudinal Studies

Longitudinal studies are crucial for tracking changes in the gut microbiome over time and their association with health outcomes. Tracking how the microbiome changes over an individual's lifetime, including during critical periods such as infancy, pregnancy, and aging, is important. Olsson et al., 2022 provide insights into how longitudinal studies can reveal patterns in microbiome composition associated with chronic diseases (Olsson et al., 2022).

Linking microbiome changes to the onset and progression of chronic diseases is another key area. Evaluating how dietary changes, probiotic treatments, or lifestyle interventions affect the microbiome and associated health outcomes over time is also essential (Zhang et al., 2022). Assessing how variations in microbial diversity correlate with health and disease across different populations will provide valuable insights.

Integrative Approaches

Integrative approaches combining microbiome research with other omics technologies will provide a holistic understanding of the gut microbiome's role in health and disease. Combining metagenomics, transcriptomics, proteomics, and metabolomics can offer a comprehensive view of the microbiome's role. Graw et al. (2021) discuss the integration of multiple omics technologies to gain insights into the microbiome's impact on health and disease (Graw et al., 2021).

Using systems biology approaches to model interactions between microbial and host systems, including predictive modeling of microbiome changes and their impacts on health, is also valuable. Leveraging integrative omics data to tailor personalized interventions based on individual microbiome profiles and other biological factors will further enhance our understanding. Applying advanced computational methods to analyze large-scale microbiome and omics data will uncover patterns that might be missed by traditional approaches.

Conclusion

This review has synthesized recent advancements in gut microbiome research, revealing its profound influence on human health. We explored the intricate relationships between the gut microbiome and various physiological, psychological, and immunological states. Key findings include the essential role of the gut microbiome in digestion, metabolism, and immune function, as well as its impact on conditions such as obesity and mental health. We also highlighted significant differences in microbiome composition across ethnic groups and the effects of diet, environment, and medication on microbiota diversity. Recent techniques such as metagenomics, metatranscriptomics, and single-cell sequencing have enhanced our understanding of these complex microbial communities.

The findings underscore the need for continued research to unravel the complexities of microbial interactions and their collective impact on health. Longitudinal studies are critical for tracking changes in the gut microbiome and their implications for chronic disease management. Integrative approaches combining microbiome research with omics technologies promise to provide a holistic understanding of microbiome functions and their therapeutic potentials. Clinically, personalized medicine based on individual microbiome profiles offers the possibility of tailored interventions that could revolutionize treatment strategies for a range of health conditions.

The gut microbiome represents a dynamic and essential component of human health, influencing numerous physiological and psychological processes. As research continues to evolve, a deeper appreciation of the microbiome's role will enhance our ability to address health challenges and develop innovative treatments. Embracing a multidisciplinary approach will be crucial for advancing our knowledge and leveraging microbiome science to improve human health outcomes.

References

- Adler, C. J., Dobney, K., Weyrich, L. S., Kaidonis, J., Walker, A. W., Haak, W., ... & Cooper, A. (2013).** Sequencing ancient calcified dental plaque shows changes in oral microbiota with dietary shifts of the Neolithic and Industrial revolutions. *Nature genetics*, 45(4), 450-455.
- Alam, M. T., Amos, G. C., Murphy, A. R., Murch, S., Wellington, E. M., & Arasaradnam, R. P. (2020).** Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. *Gut pathogens*, 12, 1-8.
- Almeida, A., Mitchell, A. L., Boland, M., Forster, S. C., Gloor, G. B., Tarkowska, A., ... & Finn, R. D. (2019).** A new genomic blueprint of the human gut microbiota. *Nature*, 568 (7753), 499-504.
- Al-Mustanjid, M., Mahmud, S. H., Royel, M. R. I., Rahman, M. H., Islam, T., Rahman, M. R., & Moni, M. A. (2020).** Detection of molecular signatures and pathways shared in inflammatory bowel disease and colorectal cancer: a bioinformatics and systems biology approach. *Genomics*, 112(5), 3416-3426.
- Alpino, G. D. C. Á., Pereira-Sol, G. A., Dias, M. D. M. E., Aguiar, A. S. D., & Peluzio, M. D. C. G. (2024).** Beneficial effects of butyrate on brain functions: a view of epigenetic. *Critical Reviews in Food Science and Nutrition*, 64(12), 3961-3970.
- Alzahrani, H., & Fernstad, S. (2023).** An investigation into various visualization tools for complex biological networks. *Information Visualization*, 22(4), 323-339.
- Amabebe, E., Robert, F. O., Agbalalah, T., & Orubu, E. S. (2020).** Microbial dysbiosis-induced obesity: role of gut microbiota in homeostasis of energy metabolism. *British Journal of Nutrition*, 123(10), 1127-1137.
- Amarasinghe, S. L., Su, S., Dong, X., Zappia, L., Ritchie, M. E., & Gouil, Q. (2020).** Opportunities and challenges in long-read sequencing data analysis. *Genome biology*, 21(1), 30.
- Arikan, M., & Muth, T. (2023).** Integrated multi-omics analyses of microbial communities: a review of the current state and future directions. *Molecular Omics*.
- Armour, C. R., Nayfach, S., Pollard, K. S., & Sharpton, T. J. (2019).** A metagenomic meta-analysis reveals functional signatures of health and disease in the human gut microbiome. *MSystems*, 4(4), 10-1128.
- Arnone, D., Chabot, C., Heba, A. C., Kökten, T., Caron, B., Hansmann, F., ... & Peyrin-Biroulet, L. (2022).** Sugars and gastrointestinal health. *Clinical Gastroenterology and Hepatology*, 20(9), 1912-1924.
- Aron-Wisniewsky, J., Warmbrunn, M. V., Nieuwdorp, M., & Clément, K. (2021).** Metabolism and metabolic disorders and the microbiome: the intestinal microbiota associated with obesity, lipid metabolism, and metabolic health—pathophysiology and therapeutic strategies. *Gastroenterology*, 160(2), 573-599.
- Aziz, T., Khan, A. A., Tzora, A., Voidarou, C., & Skoufos, I. (2023).** Dietary implications of the bidirectional relationship between the gut microflora and inflammatory diseases with special emphasis on irritable bowel disease: current and future perspective. *Nutrients*, 15(13), 2956.
- Bashiardes, S., Zilberman-Schapira, G., & Elinav, E. (2016).** Use of metatranscriptomics in microbiome research. *Bioinformatics and biology insights*, 10, BBI-S34610.
- Beghini, F., McIver, L. J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S., ... & Segata, N. (2021).** Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. *elife*, 10, e65088.
- Belkaid, Y., & Hand, T. W. (2014).** Role of the microbiota in immunity and inflammation. *Cell*, 157(1), 121-141.
- Belkaid, Y., & Harrison, O. J. (2017).** Homeostatic immunity and the microbiota. *Immunity*, 46(4), 562-576.

Bischoff, S. C., Nguyen, N. K., Seethaler, B., Beisner, J., Kügler, P., & Stefan, T. (2022). Gut microbiota patterns predicting long-term weight loss success in individuals with obesity undergoing nonsurgical therapy. *Nutrients*, 14(15), 3182.

Blaak, E. E., Canfora, E. E., Theis, S., Frost, G., Groen, A. K., Mithieux, G., ... & Verbeke, K. (2020). Short chain fatty acids in human gut and metabolic health. *Beneficial microbes*, 11(5), 411-455.

Blaser, M. J., & Falkow, S. (2009). What are the consequences of the disappearing human microbiota? *Nature Reviews Microbiology*, 7(12), 887-894.

Blaser, M. J. (2016). Antibiotic use and its consequences for the normal microbiome. *Science*, 352(6285), 544-545.

Bode, L. (2012). Human milk oligosaccharides: Every baby needs a sugar mama. *Glycobiology*, 22(9), 1147-1162.

Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*, 30(15), 2114-2120.

Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., ... & Caporaso, J. G. (2019). Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nature biotechnology*, 37(8), 852-857.

Bongaerts, M., Bonte, R., Demirdas, S., Jacobs, E. H., Oussoren, E., van der Ploeg, A. T., ... & Ruijter, G. J. (2020). Using out-of-batch reference populations to improve untargeted metabolomics for screening inborn errors of metabolism. *Metabolites*, 11(1), 8.

Borrello, K., Lim, U., Park, S. Y., Monroe, K. R., Maskarin, G., Boushey, C. J., ... & Lampe, J. W. (2022). Dietary intake mediates ethnic differences in gut microbial composition. *Nutrients*, 14(3), 660.

Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016). Near-optimal probabilistic RNA-seq quantification. *Nature Biotechnology*, 34(5), 525-527.

Brown, C. T., Olm, M. R., Thomas, B. C., & Banfield, J. F. (2016). Measurement of bacterial replication rates in microbial communities. *Nature biotechnology*, 34(12), 1256-1263.

Canani, R. B., Di Costanzo, M., Leone, L., Pedata, M., Meli, R., & Calignano, A. (2011). Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. *World journal of gastroenterology: WJG*, 17(12), 1519.

Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., ... & Burcelin, R. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes*, 56(7), 1761-1772.

Cani, P. D., & Delzenne, N. M. (2008). The gut microbiome as a therapeutic target. *Pharmacological Research*, 61(2), 103-113.

Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., ... & Gasbarrini, A. (2017). European consensus conference on faecal microbiota transplantation in clinical practice. *Gut*, 66(4), 569-580.

Carlessi, A. S., Borba, L. A., Zugno, A. I., Quevedo, J., & Réus, G. Z. (2021). Gut microbiota-brain axis in depression: The role of neuroinflammation. *European Journal of Neuroscience*, 53(1), 222-235.

Cheng, M., Cao, L., & Ning, K. (2019). Microbiome big-data mining and applications using single-cell technologies and metagenomics approaches toward precision medicine. *Frontiers in Genetics*, 10, 972.

Chen, Y., Ma, C., Liu, L., He, J., Zhu, C., Zheng, F., ... & Dai, Y. (2021). Analysis of gut microbiota and metabolites in patients with rheumatoid arthritis and identification of potential biomarkers. *Aging (Albany NY)*, 13(20), 23689.

Chen, Y., Xu, J., & Chen, Y. (2021). Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. *Nutrients*, 13(6), 2099.

Choi, H., Rao, M. C., & Chang, E. B. (2021). Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism. *Nature Reviews Gastroenterology & Hepatology*, 18(10), 679-689.

Chu, X., Zhang, B., Koeken, V. A., Gupta, M. K., & Li, Y. (2021). Multi-omics approaches in immunological research. *Frontiers in Immunology*, 12, 668045.

Chudzik, A., Orzylowska, A., Rola, R., & Stanis, G. J. (2021). Probiotics, prebiotics and postbiotics on mitigation of depression symptoms: modulation of the brain–gut–microbiome axis. *Biomolecules*, 11(7), 1000.

Clemente, J. C., Pehrsson, E. C., Blaser, M. J., Sandhu, K., Gao, Z., Wang, B., ... & Dominguez-Bello, M. G. (2015). The microbiome of uncontacted Amerindians. *Science advances*, 1(3), e1500183.

Cockburn, D. W., & Koropatkin, N. M. (2016). Polysaccharide degradation by the intestinal microbiota and its influence on human health and disease. *Journal of molecular biology*, 428(16), 3230-3252.

Conlon, M. A., & Bird, A. R. (2014). The impact of diet and lifestyle on gut microbiota and human health. *Nutrients*, 7(1), 17-44.

Conte, M. I., Fuentes-Trillo, A., & Conde, C. D. (2024). Opportunities and tradeoffs in single-cell transcriptomic technologies. *Trends in Genetics*.

Crothers, J. W., Chu, N. D., Nguyen, L. T. T., Phillips, M., Collins, C., Fortner, K., ... & Moses, P. L. (2021). Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. *BMC gastroenterology*, 21, 1-16.

Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. *Nature Reviews Neuroscience*, 13(10), 701-712.

Cryan, J. F., & Dinan, T. G. (2017). Brain-gut-microbiota axis - mood, metabolism, and behaviour. *Nature Reviews Gastroenterology & Hepatology*, 14(2), 69-70.

Dai, Z., Ramesh, V., & Locasale, J. W. (2020). The evolving metabolic landscape of chromatin biology and epigenetics. *Nature Reviews Genetics*, 21(12), 737-753.

Dalby, M. J. (2023). Questioning the foundations of the gut microbiota and obesity.

Dar, D., Dar, N., Cai, L., & Newman, D. K. (2021). Spatial transcriptomics of planktonic and sessile bacterial populations at single-cell resolution. *Science*, 373(6556), eabi4882.

Davis, J. J., Wattam, A. R., Aziz, R. K., Bretin, T., Butler, R., Butler, R. M., ... & Stevens, R. (2020). The PATRIC Bioinformatics Resource Center: expanding data and analysis capabilities. *Nucleic acids research*, 48(D1), D606-D612.

Deris Zayeri, Z., Parsi, A., Shahrabi, S., Kargar, M., Davari, N., & Saki, N. (2023). Epigenetic and metabolic reprogramming in inflammatory bowel diseases: diagnostic and prognostic biomarkers in colorectal cancer. *Cancer Cell International*, 23(1), 264.

Philosophical Transactions of the Royal Society B, 378(1888), 20220221.

Deschasaux, M., Huybrechts, I., Murphy, N., Julia, C., Hercberg, S., Srouf, B., ... & Touvier, M. (2018). Nutritional quality of food as represented by the FSAm-NPS nutrient profiling system underlying the Nutri-Score label and cancer risk in Europe: Results from the EPIC prospective cohort study. *PLoS medicine*, 15(9), e1002651.

Dinan, T. G., & Cryan, J. F. (2017). Gut-brain axis in 2016: Brain-gut-microbiota axis - mood, metabolism and behaviour. *Nature Reviews Gastroenterology & Hepatology*, 14(2), 69-70.

Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., ... & Gingeras, T. R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*, 29(1), 15-21.

Dominguez-Bello, M. G., Costello, E. K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N., & Knight, R. (2010). Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proceedings of the National Academy of Sciences*, 107(26), 11971-11975.

Duan, M., Wang, Y., Zhang, Q., Zou, R., Guo, M., & Zheng, H. (2021). Characteristics of gut microbiota in people with obesity. *Plos one*, 16(8), e0255446.

Dunn, W. B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., ... & Human Serum Metabolome (HUSERMET) Consortium. (2011). Procedures for large-scale

metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. *Nature protocols*, 6(7), 1060-1083.

Edler, D., Klein, J., Antonelli, A., & Silvestro, D. (2021). raxmlGUI 2.0: a graphical interface and toolkit for phylogenetic analyses using RAxML. *Methods in ecology and evolution*, 12(2), 373-377.

Eicher, T. P., & Mohajeri, M. H. (2022). Overlapping mechanisms of action of brain-active bacteria and bacterial metabolites in the pathogenesis of common brain diseases. *Nutrients*, 14(13), 2661.

Einarsson, K., Ericsson, S., Ewerth, S., Reihner, E., Rudling, M., Ståhlberg, D., & Angelin, B. (1991). Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. *European journal of clinical pharmacology*, 40(Suppl 1), S53-S58.

Emwas, A. H., Roy, R., McKay, R. T., Tenori, L., Saccenti, E., Gowda, G. N., ... & Wishart, D. S. (2019). NMR spectroscopy for metabolomics research. *Metabolites*, 9(7), 123.

Ervin, S. M., Li, H., Lim, L., Roberts, L. R., Liang, X., Mani, S., & Redinbo, M. R. (2019). Gut microbial β -glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens. *Journal of Biological Chemistry*, 294(49), 18586-18599.

Escalas, A., Hale, L., Voordeckers, J. W., Yang, Y., Firestone, M. K., Alvarez-Cohen, L., & Zhou, J. (2019). Microbial functional diversity: from concepts to applications. *Ecology and Evolution*, 9(20), 12000-12016.

Espina, V., Heiby, M., Pierobon, M., & Liotta, L. A. (2007). Laser capture microdissection technology. *Expert review of molecular diagnostics*, 7(5), 647-657.

Fan, L., Ren, J., Chen, Y., Wang, Y., Guo, Z., Bu, P., ... & Cai, J. (2022). Effect of fecal microbiota transplantation on primary hypertension and the underlying mechanism of gut microbiome restoration: protocol of a randomized, blinded, placebo-controlled study. *Trials*, 23(1), 178.

Fan, Y., & Pedersen, O. (2021). Gut microbiota in human metabolic health and disease. *Nature Reviews Microbiology*, 19(1), 55-71.

Fragiadakis, G. K., Smits, S. A., Sonnenburg, E. D., Van Treuren, W., Reid, G., Knight, R., ... & Sonnenburg, J. L. (2019). Links between environment, diet, and the hunter-gatherer microbiome. *Gut Microbes*, 10(2), 216-227.

Fuentes-Trillo, A., Monzó, C., Manzano, I., Santiso-Bellón, C., Andrade, J. D. S. R. D., Gozalbo-Rovira, R., ... & Chaves, F. J. (2021). Benchmarking different approaches for norovirus genome assembly in metagenome samples. *BMC genomics*, 22, 1-12.

Fukuda, K., Ogawa, M., Taniguchi, H., & Saito, M. (2016). Molecular approaches to studying microbial communities: targeting the 16S ribosomal RNA gene. *Journal of UOEH*, 38(3), 223-232.

Gasaly, N., De Vos, P., & Hermoso, M. A. (2021). Impact of bacterial metabolites on gut barrier function and host immunity: a focus on bacterial metabolism and its relevance for intestinal inflammation. *Frontiers in immunology*, 12, 658354.

Ghosh, S., & Pramanik, S. (2021). Structural diversity, functional aspects and future therapeutic applications of human gut microbiome. *Archives of microbiology*, 203(9), 5281-5308.

Gomaa, E. Z. (2020). Human gut microbiota/microbiome in health and diseases: a review. *Antonie Van Leeuwenhoek*, 113(12), 2019-2040.

Gou, H. Z., Zhang, Y. L., Ren, L. F., Li, Z. J., & Zhang, L. (2022). How do intestinal probiotics restore the intestinal barrier?. *Frontiers in microbiology*, 13, 929346.

Gray, I. D., Kross, A. R., Renfrew, M. E., & Wood, P. (2020). Precision medicine in lifestyle medicine: the way of the future?. *American Journal of Lifestyle Medicine*, 14(2), 169-186.

Graw, S., Chappell, K., Washam, C. L., Gies, A., Bird, J., Robeson, M. S., & Byrum, S. D. (2021). Multi-omics data integration considerations and study design for biological systems and disease. *Molecular omics*, 17(2), 170-185.

Green, M., Arora, K., & Prakash, S. (2020). Microbial medicine: prebiotic and probiotic functional foods to target obesity and metabolic syndrome. *International journal of molecular sciences*, 21(8), 2890.

Groussin, M., Mazel, F., & Alm, E. J. (2020). Co-evolution and co-speciation of host-gut bacteria systems. *Cell Host & Microbe*, 28(1), 12-22.

Gupta, V. K., Paul, S., & Dutta, C. (2017). Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. *Frontiers in microbiology*, 8, 1162.

Haarhuis, J. E., Kardinaal, A., & Kortman, G. A. M. (2022). Probiotics, prebiotics and postbiotics for better sleep quality: A narrative review. *Beneficial Microbes*, 13(3), 169-182.

He, F. F., & Li, Y. M. (2020). Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: a review. *Journal of ovarian research*, 13(1), 73.

He, S., Li, H., Yu, Z., Zhang, F., Liang, S., Liu, H., ... & Lü, M. (2021). The gut microbiome and sex hormone-related diseases. *Frontiers in microbiology*, 12, 711137.

Hillesheim, E., & Brennan, L. (2023). Distinct patterns of personalised dietary advice delivered by a metatype framework similarly improve dietary quality and metabolic health parameters: secondary analysis of a randomised controlled trial. *Frontiers in Nutrition*, 10, 1282741.

Huang, K., Xu, Y., Feng, T., Lan, H., Ling, F., Xiang, H., & Liu, Q. (2024). The Advancement and Application of the Single-Cell Transcriptome in Biological and Medical Research. *Biology*, 13(6), 451.

Hussain, T., Murtaza, G., Kalhoro, D. H., Kalhoro, M. S., Metwally, E., Chughtai, M. I., ... & Khan, S. A. (2021). Relationship between gut microbiota and host-metabolism: Emphasis on hormones related to reproductive function. *Animal Nutrition*, 7(1), 1-10.

Iablokov, S. N., Klimenko, N. S., Efimova, D. A., Shashkova, T., Novichkov, P. S., Rodionov, D. A., & Tyakht, A. V. (2021). Metabolic phenotypes as potential biomarkers for linking gut microbiome with inflammatory bowel diseases. *Frontiers in Molecular Biosciences*, 7, 603740.

Iversen, K. N., Dicksved, J., Zoki, C., Fristedt, R., Pelve, E. A., Langton, M., & Landberg, R. (2022). The effects of high fiber rye, compared to refined wheat, on gut microbiota composition, plasma short chain fatty acids, and implications for weight loss and metabolic risk factors (the RyeWeight Study). *Nutrients*, 14(8), 1669.

Jiang, Y., Wu, R., Zhang, W., Xin, F., & Jiang, M. (2023). Construction of stable microbial consortia for effective biochemical synthesis. *Trends in Biotechnology*, 41(11), 1430-1441.

Ji-Chao, Z. H. O. U., & Zhang, X. W. (2019). Akkermansia muciniphila: a promising target for the therapy of metabolic syndrome and related diseases. *Chinese journal of natural medicines*, 17(11), 835-841.

Keegan, K. P., Glass, E. M., & Meyer, F. (2016). MG-RAST, a metagenomics service for analysis of microbial community structure and function. *Microbial environmental genomics (MEG)*, 207-233.

Keerthi, T. R., Narayanan, R., Sreelekshmi, K., & Honey Chandran, C. (2021). Immunity and gut microbiome: role of probiotics and prebiotics. *Probiotic Bacteria and Postbiotic Metabolites: Role in Animal and Human Health*, 61-83.

Keklik, G. (2023). Understanding evolutionary relationships and analysis methods through mega software. *INTERNATIONAL JOURNAL OF NEW HORIZONS IN THE SCIENCES*, 83-90.

Khan, M. F., & Wang, H. (2020). Environmental exposures and autoimmune diseases: contribution of gut microbiome. *Frontiers in immunology*, 10, 3094.

Kim, C. H. (2021). Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids. *Cellular & molecular immunology*, 18(5), 1161-1171.

Kurilshikov, A., Medina-Gomez, C., Bacigalupe, R., Radjabzadeh, D., Wang, J., Demirkan, A., & Zhernakova, A. (2021). Large-scale association analyses identify host factors influencing human gut microbiome composition. *Nature genetics*, 53(2), 156-165.

Kviatcovsky, D., Zheng, D., & Elinav, E. (2021). Gut microbiome and its potential link to personalized nutrition. *Current opinion in physiology*, 22, 100439.

Lenti, M. V., Rugge, M., Lahner, E., Miceli, E., Toh, B. H., Genta, R. M., ... & Di Sabatino, A. (2020). Autoimmune gastritis. *Nature Reviews Disease Primers*, 6(1), 56.

Li, F., Ye, J., Shao, C., & Zhong, B. (2021). Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: A systematic review and Meta-analysis. *Lipids in Health and Disease*, 20, 1-12.

Li, H., He, J., & Jia, W. (2016). The influence of gut microbiota on drug metabolism and toxicity. *Expert opinion on drug metabolism & toxicology*, 12(1), 31-40.

Li, H., Hsieh, K., Wong, P. K., Mach, K. E., Liao, J. C., & Wang, T. H. (2023). Single-cell pathogen diagnostics for combating antibiotic resistance. *Nature Reviews Methods Primers*, 3(1), 6.

Liu, P., Wang, Y., Yang, G., Zhang, Q., Meng, L., Xin, Y., & Jiang, X. (2021). The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis. *Pharmacological research*, 165, 105420.

Liu, X., Liu, Y., Liu, J., Zhang, H., Shan, C., Guo, Y., ... & Tang, M. (2024). Correlation between the gut microbiome and neurodegenerative diseases: a review of metagenomics evidence. *Neural Regeneration Research*, 19(4), 833-845.

Long, N., Qiao, Y., Xu, Z., Tu, J., & Lu, Z. (2020). Recent advances and application in whole-genome multiple displacement amplification. *Quantitative Biology*, 8(4), 279-294.

Lu, J., Rincon, N., Wood, D. E., Breitwieser, F. P., Pockrandt, C., Langmead, B., ... & Steinegger, M. (2022). Metagenome analysis using the Kraken software suite. *Nature protocols*, 17(12), 2815-2839.

Lucarelli, G., Loizzo, D., Ferro, M., Rutigliano, M., Vartolomei, M. D., Cantiello, F., ... & Battaglia, M. (2019). Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: An update. *Expert Review of Molecular Diagnostics*, 19(5), 377-387.

Magne, F., Gotteland, M., Gauthier, L., Zazueta, A., Pessoa, S., Navarrete, P., & Balamurugan, R. (2020). The firmicutes/bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients?. *Nutrients*, 12(5), 1474.

Maranga, M., Szczerbiak, P., Bezshapkin, V., Gligorijevic, V., Chandler, C., Bonneau, R., ... & Kosciolk, T. (2023). Comprehensive functional annotation of metagenomes and microbial genomes using a deep learning-based method. *Msystems*, 8(2), e01178-22.

Margoob, M., Kouser, S., & Jan, N. (2024). Serotonin: The Link between Gut Microbiome and Brain. In *Serotonin-Neurotransmitter and Hormone of Brain, Bowels and Blood*. IntechOpen.

Matchado, M. S., Lauber, M., Reitmeier, S., Kacprowski, T., Baumbach, J., Haller, D., & List, M. (2021). Network analysis methods for studying microbial communities: A mini review. *Computational and structural biotechnology journal*, 19, 2687-2698.

May, K. S., & Den Hartigh, L. J. (2021). Modulation of adipocyte metabolism by microbial short-chain fatty acids. *Nutrients*, 13(10), 3666.

McElhinney, J. M., Catacutan, M. K., Mawart, A., Hasan, A., & Dias, J. (2022). Interfacing machine learning and microbial omics: a promising means to address environmental challenges. *Frontiers in Microbiology*, 13, 851450.

Medjaoui, I., Rahmani, B., Talhi, M., Mahammi, F. Z., Moghtit, F. Z., Mehtar, N., & Gaouar, S. B. S. (2016). Isolation and Characterization of Lactic Acid Bacteria from Human Milk and Newborn Feces. *Journal of Pure & Applied Microbiology*, 10(4).

Mitrea, L., Nemeş, S. A., Szabo, K., Teleky, B. E., & Vodnar, D. C. (2022). Guts imbalance imbalances the brain: a review of gut microbiota association with neurological and psychiatric disorders. *Frontiers in medicine*, 9, 813204.

Miyauchi, E., Shimokawa, C., Steimle, A., Desai, M. S., & Ohno, H. (2023). The impact of the gut microbiome on extra-intestinal autoimmune diseases. *Nature Reviews Immunology*, 23(1), 9-23.

Molinero, N., Ruiz, L., Sánchez, B., Margolles, A., & Delgado, S. (2019). Intestinal bacteria interplay with bile and cholesterol metabolism: implications on host physiology. *Frontiers in physiology*, 10, 185.

Molska, M., Mruczyk, K., Cisek-Woźniak, A., Prokopowicz, W., Szydelko, P., Jakuszczyńska, Z., ... & Trocholewska, M. (2024). The Influence of Intestinal Microbiota on BDNF Levels. *Nutrients*, 16(17), 2891.

Moszak, M., Szulińska, M., & Bogdański, P. (2020). You are what you eat—the relationship between diet, microbiota, and metabolic disorders—a review. *Nutrients*, 12(4), 1096.

Mukherjee, A., D’Ugo, E., Giuseppetti, R., Magurano, F., & Cotter, P. D. (2023). Metagenomic approaches for understanding microbial communities in contaminated environments: Bioinformatic tools, case studies and future outlook. In *Metagenomics to bioremediation* (pp. 103-156). Academic Press.

Musazadeh, V., Zarezadeh, M., Faghfour, A. H., Keramati, M., Jamilian, P., Jamilian, P., ... & Farnam, A. (2023). Probiotics as an effective therapeutic approach in alleviating depression symptoms: an umbrella meta-analysis. *Critical Reviews in Food Science and Nutrition*, 63(26), 8292-8300.

Musich, R., Cadle-Davidson, L., & Osier, M. V. (2021). Comparison of short-read sequence aligners indicates strengths and weaknesses for biologists to consider. *Frontiers in Plant Science*, 12, 657240.

Nguyen, T. M., Shafi, A., Nguyen, T., & Draghici, S. (2019). Identifying significantly impacted pathways: a comprehensive review and assessment. *Genome biology*, 20, 1-15.

Ojala, T., Häkkinen, A. E., Kankuri, E., & Kankainen, M. (2023). Current concepts, advances, and challenges in deciphering the human microbiota with metatranscriptomics. *Trends in Genetics*, 39(9), 686-702.

Olsson, L. M., Boulund, F., Nilsson, S., Khan, M. T., Gummesson, A., Fagerberg, L., ... & Bäckhed, F. (2022). Dynamics of the normal gut microbiota: a longitudinal one-year population study in Sweden. *Cell host & microbe*, 30(5), 726-739.

O’Riordan, K. J., Collins, M. K., Moloney, G. M., Knox, E. G., Aburto, M. R., Fülling, C., ... & Cryan, J. F. (2022). Short chain fatty acids: microbial metabolites for gut-brain axis signalling. *Molecular and Cellular Endocrinology*, 546, 111572.

Palma, A. (2024). Unveiling microglial heterogeneity from single-cell transcriptomics in neurodegenerative diseases. *bioRxiv*, 2024-08.

Payling, L., Fraser, K., Loveday, S. M., Sims, I., Roy, N., & McNabb, W. (2020). The effects of carbohydrate structure on the composition and functionality of the human gut microbiota. *Trends in Food Science & Technology*, 97, 233-248.

Peredo-Lovillo, A., Romero-Luna, H. E., & Jiménez-Fernández, M. (2020). Health promoting microbial metabolites produced by gut microbiota after prebiotics metabolism. *Food Research International*, 136, 109473.

Pérez-Rubio, P., Lottaz, C., & Engelmann, J. C. (2019). FastqPuri: high-performance preprocessing of RNA-seq data. *BMC bioinformatics*, 20, 1-11.

Pham, V. T., Dold, S., Rehman, A., Bird, J. K., & Steinert, R. E. (2021). Vitamins, the gut microbiome and gastrointestinal health in humans. *Nutrition Research*, 95, 35-53.

Rani, K., Kaur, G., & Ali, S. A. (2023). Probiotic-prebiotic therapeutic potential: a new horizon of microbial biotherapy to reduce female reproductive complications. *PharmaNutrition*, 24, 100342.

Rebersek, M. (2021). Gut microbiome and its role in colorectal cancer. *BMC cancer*, 21(1), 1325.

Reichart, N. J., Jay, Z. J., Krukenberg, V., Parker, A. E., Spietz, R. L., & Hatzenpichler, R. (2020). Activity-based cell sorting reveals responses of uncultured archaea and bacteria to substrate amendment. *The ISME journal*, 14(11), 2851-2861.

Rezende, E. S. V., Lima, G. C., & Naves, M. M. V. (2021). Dietary fibers as beneficial microbiota modulators: A proposed classification by prebiotic categories. *Nutrition*, 89, 111217.

Rifkin, R. F., Vikram, S., Ramond, J. B., Rey-Iglesia, A., Brand, T. B., Porraz, G., & Hansen, A. J. (2020). Multi-proxy analyses of a mid-15th century Middle Iron Age Bantu-speaker palaeo-faecal

specimen elucidates the configuration of the ‘ancestral’ sub-Saharan African intestinal microbiome. *Microbiome*, 8, 1-23.

Roopashree, K. M., & Naik, D. (2019). Advanced method of secondary metabolite extraction and quality analysis. *Journal of Pharmacognosy and Phytochemistry*, 8(3), 1829-1842.

Roy, S., & Dhaneshwar, S. (2023). Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. *World Journal of Gastroenterology*, 29(14), 2078.

Ruan, W., Engevik, M. A., Spinler, J. K., & Versalovic, J. (2020). Healthy human gastrointestinal microbiome: composition and function after a decade of exploration. *Digestive diseases and sciences*, 65, 695-705.

Sánchez-Quinto, A., Cerqueda-García, D., Falcón, L. I., Gaona, O., Martínez-Correa, S., Nieto, J., & G-Santoyo, I. (2020). Gut microbiome in children from indigenous and urban communities in México: Different subsistence models, different microbiomes. *Microorganisms*, 8(10), 1592.

Sarkar, A., Yoo, J. Y., Valeria Ozorio Dutra, S., Morgan, K. H., & Groer, M. (2021). The association between early-life gut microbiota and long-term health and diseases. *Journal of clinical medicine*, 10(3), 459.

Schalla, M. A., & Stengel, A. (2020). Effects of microbiome changes on endocrine ghrelin signaling—A systematic review. *Peptides*, 133, 170388.

Seo, H., & Song, H. Y. (2024). Perspectives on Microbiome Therapeutics in Infectious Diseases: A Comprehensive Approach beyond Immunology and Microbiology.

Sequeira, J. C., Rocha, M., Alves, M. M., & Salvador, A. F. (2022). UPIMAPI, reCOGnizer and KEGG Charter: Bioinformatics tools for functional annotation and visualization of (meta)-omics datasets. *Computational and Structural Biotechnology Journal*, 20, 1798-1810.

Shaffer, J. P., Carpenter, C. S., Martino, C., Salido, R. A., Minich, J. J., Bryant, M., ... & Knight, R. (2022). A comparison of six DNA extraction protocols for 16S, ITS and shotgun metagenomic sequencing of microbial communities. *Biotechniques*, 73(1), 34-46.

Shaheen, W. A., Quraishi, M. N., & Iqbal, T. H. (2022). Gut microbiome and autoimmune disorders. *Clinical and Experimental Immunology*, 209(2), 161-174.

Silva, R., Padovani, K., Góes, F., & Alves, R. (2021). geneRFinder: gene finding in distinct metagenomic data complexities. *BMC bioinformatics*, 22, 1-17.

Singh, R., Zogg, H., Wei, L., Bartlett, A., Ghoshal, U. C., Rajender, S., & Ro, S. (2021). Gut microbial dysbiosis in the pathogenesis of gastrointestinal dysmotility and metabolic disorders. *Journal of neurogastroenterology and motility*, 27(1), 19.

Sisk-Hackworth, L., Kelley, S. T., & Thackray, V. G. (2023). Sex, puberty, and the gut microbiome. *Reproduction*, 165(2), R61-R74.

Snigdha, S., Ha, K., Tsai, P., Dinan, T. G., Bartos, J. D., & Shahid, M. (2022). Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan. *Pharmacology & Therapeutics*, 231, 107978.

Stark, R., Grzelak, M., & Hadfield, J. (2019). RNA sequencing: the teenage years. *Nature Reviews Genetics*, 20(11), 631-656.

Stojanov, S., Berlec, A., & Štrukelj, B. (2020). The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. *Microorganisms*, 8(11), 1715.

Subramanian, I., Verma, S., Kumar, S., Jere, A., & Anamika, K. (2020). Multi-omics data integration, interpretation, and its application. *Bioinformatics and biology insights*, 14, 1177932219899051.

Sun, Y., Zuo, T., Cheung, C. P., Gu, W., Wan, Y., Zhang, F., ... & Miao, Y. (2021). Population-level configurations of gut mycobiome across 6 ethnicities in urban and rural China. *Gastroenterology*, 160(1), 272-286.

Tan, S., Santolaya, J. L., Wright, T. F., Liu, Q., Fujikawa, T., Chi, S., ... & Burstein, E. (2024). Interaction between the gut microbiota and colonic enteroendocrine cells regulates host metabolism. *Nature Metabolism*, 1-16.

Thomson, C. A., Morgan, S. C., Ohland, C., & McCoy, K. D. (2022). From germ-free to wild: modulating microbiome complexity to understand mucosal immunology. *Mucosal Immunology*, 15(6), 1085-1094.

Ting, N. L. N., Lau, H. C. H., & Yu, J. (2022). Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. *Gut*, 71(7), 1412-1425.

Toya, T., Corban, M. T., Marrietta, E., Horwath, I. E., Lerman, L. O., Murray, J. A., & Lerman, A. (2020). Coronary artery disease is associated with an altered gut microbiome composition. *PloS one*, 15(1), e0227147.

Uddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., ... & Koirala, N. (2021). Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. *Journal of infection and public health*, 14(12), 1750-1766.

Um, C. Y., Peters, B. A., Choi, H. S., Oberstein, P., Beggs, D. B., Usyk, M., ... & Ahn, J. (2023). Grain, gluten, and dietary fiber intake influence gut microbial diversity: data from the food and microbiome longitudinal investigation. *Cancer Research Communications*, 3(1), 43-53.

Vallianou, N., Stratigou, T., Christodoulatos, G. S., Tsigalou, C., & Dalamaga, M. (2020). Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives. *Current obesity reports*, 9, 179-192.

Van der Hee, B., & Wells, J. M. (2021). Microbial regulation of host physiology by short-chain fatty acids. *Trends in Microbiology*, 29(8), 700-712.

Venneri, M. A., Franceschini, E., Sciarra, F., Rosato, E., D'ettore, G., & Lenzi, A. (2022). Human genital tracts microbiota: dysbiosis crucial for infertility. *Journal of Endocrinological Investigation*, 45(6), 1151-1160.

Wang, B., Kong, Q., Li, X., Zhao, J., Zhang, H., Chen, W., & Wang, G. (2020). A high-fat diet increases gut microbiota biodiversity and energy expenditure due to nutrient difference. *Nutrients*, 12(10), 3197.

Wang, N., Chen, L., Yi, K., Zhang, B., Li, C., & Zhou, X. (2024). The effects of microbiota on reproductive health: A review. *Critical Reviews in Food Science and Nutrition*, 64(6), 1486-1507.

Wensel, C. R., Pluznick, J. L., Salzberg, S. L., & Sears, C. L. (2022). Next-generation sequencing: insights to advance clinical investigations of the microbiome. *The Journal of clinical investigation*, 132(7).

Wishart, D. S., Feunang, Y. D., Marcu, A., Guo, A. C., Liang, K., Vázquez-Fresno, R., ... & Scalbert, A. (2018). HMDB 4.0: the human metabolome database for 2018. *Nucleic acids research*, 46(D1), D608-D617.

Williams, N., Vella, R., Zhou, Y., Gao, H., Mass, K., Townsel, C., ... & Luo, G. (2022). Investigating the origin of the fetal gut and placenta microbiome in twins. *The Journal of Maternal-Fetal & Neonatal Medicine*, 35(25), 7025-7035.

Witkowski, M., Weeks, T. L., & Hazen, S. L. (2020). Gut microbiota and cardiovascular disease. *Circulation research*, 127(4), 553-570.

Wu, H., & Chiou, J. (2021). Potential benefits of probiotics and prebiotics for coronary heart disease and stroke. *Nutrients*, 13(8), 2878.

Xu, T., Wu, X., Liu, J., Sun, J., Wang, X., Fan, G., ... & Zhang, Y. (2022). The regulatory roles of dietary fibers on host health via gut microbiota-derived short chain fatty acids. *Current Opinion in Pharmacology*, 62, 36-42.

Yang, C., Chowdhury, D., Zhang, Z., Cheung, W. K., Lu, A., Bian, Z., & Zhang, L. (2021). A review of computational tools for generating metagenome-assembled genomes from metagenomic sequencing data. *Computational and Structural Biotechnology Journal*, 19, 6301-6314.

Yang, Q., Liang, Q., Balakrishnan, B., Belobrajdic, D. P., Feng, Q. J., & Zhang, W. (2020). Role of dietary nutrients in the modulation of gut microbiota: a narrative review. *Nutrients*, 12(2), 381.

Yoo, J. Y., Groer, M., Dutra, S. V. O., Sarkar, A., & McSkimming, D. I. (2020). Gut microbiota and immune system interactions. *Microorganisms*, 8(10), 1587.

Yousefi, B., Melograna, F., Galazzo, G., van Best, N., Mommers, M., Penders, J., ... & Van Steen, K. (2023). Capturing the dynamics of microbial interactions through individual-specific networks. *Frontiers in microbiology*, 14, 1170391.

Yu, Y., Wen, H., Li, S., Cao, H., Li, X., Ma, Z., ... & Huang, S. (2022). Emerging microfluidic technologies for microbiome research. *Frontiers in Microbiology*, 13, 906979.

Zeki, Ö. C., Eylem, C. C., Reçber, T., Kır, S., & Nemutlu, E. (2020). Integration of GC–MS and LC–MS for untargeted metabolomics profiling. *Journal of Pharmaceutical and Biomedical Analysis*, 190, 113509.

Zhang, Y., Chen, H., Lu, M., Cai, J., Lu, B., Luo, C., & Dai, M. (2022). Habitual diet pattern associations with gut microbiome diversity and composition: results from a Chinese adult cohort. *Nutrients*, 14(13), 2639.

Zhang, W., Qu, W., Wang, H., & Yan, H. (2021). Antidepressants fluoxetine and amitriptyline induce alterations in intestinal microbiota and gut microbiome function in rats exposed to chronic unpredictable mild stress. *Translational psychiatry*, 11(1), 131.

Zhang, Z. H., Jhaveri, D. J., Marshall, V. M., Bauer, D. C., Edson, J., Narayanan, R. K. & Zhao, Q. Y. (2014). A comparative study of techniques for differential expression analysis on RNA-Seq data. *PloS one*, 9(8), e103207.

Zheng, D., Liwinski, T., & Elinav, E. (2020). Interaction between microbiota and immunity in health and disease. *Cell research*, 30(6), 492-506.

Zikou, E., Koliaki, C., & Makrilakis, K. (2024). The Role of Fecal Microbiota Transplantation (FMT) in the Management of Metabolic Diseases in Humans: A Narrative Review. *Biomedicines*, 12(8), 1871.